Apellis制药 APLS 深 沪
已收盘 03-27 16:00:00 美东时间
16.97
-0.670
-3.80%
华盛通- 最 高17.61
- 今 开17.55
- 成交量 176.27万股
- 最 低 16.97
- 昨 收 17.64
- 总市值 21.69亿
- 52周最高 30.48
- 市盈率 静 98.43
- 换手率 1.38%
- 52周最低 16.10
- 委 比 26.87%
- 总股本 1.28亿
- 历史最高 94.75
- 量 比 0.60
- 振 幅 3.63%
- 历史最低 11.45
- 每 手 1
- 风险率 3.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Cantor Fitzgerald Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $31
Cantor Fitzgerald analyst Steve Seedhouse maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target from $35 to $31.
03-18 21:40
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Apellis wins new Buy at Roth on Syfovre prospects
Roth Capital Partners launched its coverage of Apellis Pharmaceuticals (APLS) with a Buy recommendation and a $31 target on Friday, noting that despite a ~75% decline from its 2023 peak, the biotech r...
03-13 23:43
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Mizuho Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $20
Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from $19 to $20.
03-05 21:08
Apellis Names Former Pfizer CSO Mikael Dolsten to Board
Apellis Names Former Pfizer CSO Mikael Dolsten to Board Apellis Pharmaceuticals Inc. said Mikael Dolsten, M.D., Ph.D., joined its board of directors effective March 1. Dolsten most recently served at Pfizer for more than 16 years as chief scientific officer and president of worldwide research, devel
03-02 20:00
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $48
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $45 to $48.
02-25 19:51
Apellis Q4 product revenue driven by SYFOVRE sales
Apellis Q4 product revenue driven by SYFOVRE sales Overview Biopharmaceutical company reported Q4 product revenue of $190 mln, driven by SYFOVRE sales Net income for 2025 was $22 mln, compared to a net loss in 2024 Company plans regulatory submission for SYFOVRE prefilled syringe in 2026 Outlook Ape
02-24 20:12
